Does GALT pay a dividend and is it safe?

Galectin Therapeutics Inc. (GALT) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / GALT / dividends

SPRY (20) AVIR (33) EBS (48) CYPH (42) ⌘ Pro Terminal →

Galectin Therapeutics Inc. (GALT) Dividend Safety Gauge & 10-Year DRIP Compounder

$3.33 +0.30% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.33

Galectin Therapeutics Inc. (GALT) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $335.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GALT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GALT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Galectin Therapeutics Inc. (NASDAQ: GALT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $3.33 (+0.30% 1D, market cap $335.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, GALT ranks #535 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GALT compare to SPRY and AVIR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GALT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SPRY (ARS Pharmaceuticals Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $336.1M) and AVIR (Atea Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $329.6M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GALT?

▼

Per GALT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001133416), Galectin Therapeutics Inc. generated $56.2M in revenue (-52.7% YoY), -$30.8M in net income, and -$23.9M in free cash flow against $19.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.33 (-0.14%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-9.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GALT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY GALT SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (30% of score)

FRED Regime × Technicals: 25% of 52W Range • RSI-14 at 42.4 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$3.69-7% Next Q

Q2 (-2Q)

Grade D$3.43-1.5% Next Q

Q3 (-1Q)

Grade D$3.38-1.5% Next Q

Current

Grade D-$3.33-8.1% Hist 90D α

Trajectory: D (45) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GALT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GALT currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.80) and Max Pain ($3.50) forces dealer call-delta covering toward $7.49.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GALT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “GALT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GALT)

✓Walkthrough of GALT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GALT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +45.41%🛡️ HOLDING TREND SUPPORT

2026-11-03O $3.52H $3.52L $3.32C $3.33VOL 174.8K

RES: $3.82SUP: $3.15SMA50: $3.80SMA200: $3.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GALT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GALT Butterfly Map → + Track GALT →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -52.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on GALT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GALT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GALT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GALT)

Health Care Rank #535 of 1015 ⚔️ SPRY vs GALT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GALT vs. SPRY, AVIR, EBS, CYPH)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Galectin Therapeutics Inc. (GALT) ranks #535 by composite RQD confidence (37/100, grade D-) and #502 by equity capitalization ($335.6M). Within this direct 5-issuer industry benchmark cohort, EBS leads on earnings valuation at 7.0x trailing P/E, while EBS leads on capital efficiency and profitability with 8.9% ROIC and 56.1% gross margin. EBS currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with GALT at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GALT ACTIVE Galectin Therapeutics Inc.	D-	37/100	—	—	-35.0%	+0.30%	$335.6M	Benchmark Subject
SPRY ARS Pharmaceuticals Inc.	E	20/100	—	—	-35.0%	-9.76%	$336.1M	/spry-vs-galt →
AVIR Atea Pharmaceuticals Inc.	E	33/100	—	—	-35.0%	-0.24%	$329.6M	/avir-vs-galt →
EBS Emergent BioSolutions Inc.	D	48/100	7.0x	56.1%	8.9%	-5.43%	$349.2M	/ebs-vs-galt →
CYPH Cypherpunk Technologies Inc.	D-	42/100	71.3x	—	-23.3%	-20.80%	$321.1M	/cyph-vs-galt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001133416 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Galectin Therapeutics Inc. (GALT) reported GAAP revenue of $56.2M (-52.7% vs. FY2024 revenue of $118.8M , and -47.2% cumulative change since FY2023) , GAAP net income of -$30.8M, operating cash flow of -$23.9M, and free cash flow of -$23.9M (+42.8% YoY). On the balance sheet, GALT closed FY2025 with $19.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$56.2M	-$30.8M	-$23.9M	-$23.9M	$19.5M	—
FY2024 (FY)	2024-12-31	$118.8M	-$47.0M	-$41.8M	-$41.8M	$17.5M	—
FY2023 (FY)	2023-12-31	$106.6M	-$41.1M	-$33.0M	-$33.0M	—	—

3. GALT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GALT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does GALT compare to SPRY and AVIR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for GALT?

Where is GALT trading relative to its 50-day, 200-day, and 52-week technical levels?

GALT last traded at $3.33 (+0.30% on volume of 117,171 shares), positioning the stock -12.37% below its 50-day simple moving average ($3.80) and +3.74% above its 200-day simple moving average ($3.21). Across its 52-week range of $2.03 to $7.13, GALT sits at the 25.5% percentile with a 14-day RSI of 42.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.91 to $3.75).

Direct Sub-Reports: GALT RQD Cockpit GALT 12M Forecast GALT Earnings & Move GALT Dividends & DRIP GALT Insiders & 13F GALT Whale Options GALT Profit Sankey GALT News & Why

ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ SEC XBRL & RQD VERIFIED

GALT — Galectin Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Galectin Therapeutics Inc. (GALT) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $3.33 (+0.30% 1D, market capitalization $335.6M).

Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -6.71%.
Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (11/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Galectin Therapeutics Inc. Is a NASDAQ-listed company in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It operates with a market capitalization of $0.4B. Revenue is reported as — in each of the three listed fiscal years.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Galectin Therapeutics Inc. (GALT) reported $56.2M in annual revenue (up from $118.8M in FY2024, -52.7% YoY) and -$30.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($106.6M revenue, -$41.1M net income) through FY2025, GALT scaled operating cash flow to -$23.9M and free cash flow to -$23.9M, backed by $19.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -6.71% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $2.03 – $7.13 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context is the Health Care classification and the beta of 1.0.

Key Question #1: Can GALT sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $56.2M and free cash flow of -$23.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is GALT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

GALT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Galectin Therapeutics Inc. (GALT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GALT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 21h ago

Galectin Therapeutics Inc. (GALT) Seasonal Returns Chart

Yahoo! Finance Canada report covering Galectin Therapeutics Inc. (GALT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Seeking Alpha • 1d ago

Galectin: $105M Debt Conversion Clears The Balance Sheet, But Phase 3 Partnership Is Critical

Seeking Alpha report covering Galectin Therapeutics Inc. (GALT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above Two Hundred Day Moving Average - Here's Why

MarketBeat report covering Galectin Therapeutics Inc. (GALT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

GALECTIN THERAPEUTICS INC SEC Filing (Oct 13, 2026)

Stock Titan report covering Galectin Therapeutics Inc. (GALT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Galectin Therapeutics (NASDAQ:GALT) Stock Price Breaks Above 200 Day Moving Average - Here's Why

MarketBeat report covering Galectin Therapeutics Inc. (GALT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Galectin Therapeutics (GALT) Slips 1.35% to $3.66 as Shares Sit Between Key Levels - Call Dominated

https://www.siam.in/ report covering Galectin Therapeutics Inc. (GALT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GALT Bull vs. Bear Conversation Board — What's Your Call at $3.33?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GALT 🐻 33% BEARISH CONVICTION

AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $4.02 (+21.1%)

📌 Pinned Debate

The forensic balance sheet pillar scores 10/20 with an Altman Z of 2.5 and Debt/Equity of 0.5, and a $105M debt conversion is cited as

The forensic balance sheet pillar scores 10/20 with an Altman Z of 2.5 and Debt/Equity of 0.5, and a $105M debt conversion is cited as clearing the balance sheet.. When you look under the hood at GALT, Fundamental Cash Engine is 8/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (5/20) has been quietly accumulating below $7.13. My 12M target is $4.02.

SectorRotator 🐂 BULL

@AlphaFlow_Cap Agree on the RQD 37/100 quality, though with 1.0 beta I'm scaling in with half-size at $3.32 and keeping dry powder in case we test $3.09.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $2.62 (-21.1%)

Spot @ $3.32

ROIC is -35%, FCF yield is -6.71%, and the company reported operating losses in every listed period with zero reported revenue.

Fading this rally in GALT at $3.32. ROIC is -35%, FCF yield is -6.71%, and the company reported operating losses in every listed period with zero reported revenue.. With a beta of 1.0 and the stock sitting at $3.32 (52-wk range $2.03–$7.13), the easy multiple expansion is already priced in.